Surveillance of levofloxacin resistance in helicobacter pylori isolates in Bogotá-Colombia (2009-2014)

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Trespalacios Rangél, Alba A ^a   Otero, William ^b   Arévalo Galvis, Azucena ^a   Poutou Piñales, Raúl A ^a   Rimbara, Emiko ^c,d   Graham, David Y ^c,d  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; LEVOFLOXACIN; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING);

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CHRONIC GASTRITIS; COLOMBIA; FEMALE; GASTROSCOPY; GENE STRUCTURE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; QUINOLONE RESISTANCE DETERMINING REGION; ADOLESCENT; DRUG EFFECTS; GENETICS; HELICOBACTER INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MUTATION; PREVALENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; COLOMBIA; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LEVOFLOXACIN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; PREVALENCE; YOUNG ADULT;

EID: 84980009981     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0160007     Document Type: Article

References (52)

1. Liu Y, Ponsioen CIJ, Xiao S, Tytgat GNJ, Ten Kate FJW (2005) Geographic pathology of Helicobacter pylori gastritis. Helicobacter 10: 107-113. PMID: 15810940
2. Rimbara E, Fischbach LA, Graham DY (2011) Optimal therapy for Helicobacter pylori infections. Nature Review 8: 79-88. doi: 10.1038/nrgastro.2010.210
3. Testerman TL, Morris J (2014) Beyond the stomach: An updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World Journal of Gastroenterology 20: 12781-12808. doi: 10.3748/wjg.v20.i36.12781 PMID: 25278678
4. Howden CW, Hunt RH (1998) Guidelines for the management of Helicobacter pylori. Ad Hoc Committee on practice parameters of the American College of Gastroenterology. American Journal of Gastroenterology 93: 2330-2338. PMID: 9860388
5. Bourke B, Ceponis P, Chiba N, Czinn S, Ferraro R, et al. (2005) Canadian Helicobacter study group consensus conference: update on the approach to Helicobacter pylori infection in children and adolescents-an evidence-based evaluation. Canadian Journal of Gastroenterology 19: 399-408. PMID: 16010300
6. Caselli M, Zullo A, Maconi G, Parente F, Alvisi V, et al. (2007) Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Digestive and Liver Disease 39: 782-789. PMID: 17606419
7. Chey WD, Wong BC (2007) American college ofgastroenterology guideline on the management of Helicobacter pylori infection. American Journal of Gastroenterology 102: 1808-1825. PMID: 17608775
8. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, et al. (2009) Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. Journal of Gastroenterology and Hepatology 24: 1587-1600. doi: 10.1111/j.1440-1746.2009.05982.x PMID: 19788600
9. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, et al. (2012) Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report. Gut 61: 646-664. doi: 10.1136/gutjnl-2012-302084 PMID: 22491499
10. Graham DY, Fischbach L (2010) Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59: 1143-1153. doi: 10.1136/gut.2009.192757 PMID: 20525969
11. Graham DY, Lu H, Yamaoka Y (2007) A report card to grade Helicobacter pylori therapy. Helicobacter 12: 275-278. PMID: 17669098
12. Graham DY, Lu H, Yamaoka Y (2008) Therapy for Helicobacter pylori Infection can be improved: sequential therapy and beyond. Drugs 68: 725-736. PMID: 18416582
13. Cammarota G, Cianci R, Cannizzaro O, Cuoco L, Pirozzi G, et al. (2000) Eficacy of two one-week rabeprazole/levofoxacin-based triple therapies for Helicobacter pylori infection. Alimentary Pharmacology Therapeutics 14: 1339-1343. PMID: 11012480
14. Miyachi H, Miki I, Aoyama N, Shirasaka D, Matsumoto Y, et al. (2006) Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter 11: 243-249. PMID: 16882327
15. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, et al. (2010) Worldwide H. pylori antibiotic resistance: A systematic review Journal of Gastrointestinal Liver Disese 19: 409-414.
16. Wang LH, Cheng H, Hu FL, Li J (2010) Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains. World Journal of Gastroenterology 16: 2272-2277. doi: 10.3748/wjg.v16.i18.2272 PMID: 20458765
17. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, et al. (2013) Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62: 34-42. doi: 10.1136/ gutjnl-2012-302254 PMID: 22580412
18. Chuah S-K, Tai W-C, Lee C-H, Liang C-M, Hu T-H (2014) Quinolone-containing therapies in the eradication of Helicobacter pylori. BioMed Research International 2014: Article ID 151543. doi: 10.1155/ 2014/151543 PMID: 25243116
19. Liou J-M, Chang C-Y, Chen M-J, Chen C-C, Fang Y-J, et al. (2015) The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and Its relation to virulence factors-A nationwide study. Plos One 10: e0124199. doi: 10.1371/journal.pone.0124199 PMID: 25942450
20. Bogaerts P, Berhin C, Nizet H, Glupczynski Y (2006) Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 11: 441-445. doi: 10.1111/j.1523-5378.2006.00436.x PMID: 16961806
21. Cattoir V, Nectoux J, Lascols C, Deforges L, Delchier JC, et al. (2007) Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. International Journal Antimicrobial Agents 29: 389-396.
22. Hung KH, Sheu BS, Chang WL, Wu HM, Liu CC, et al. (2009) Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 14: 61-65. doi: 10.1111/j.1523-5378.2009.00655.x PMID: 19191898
23. Murakami K, Okimoto T, Kodama M, Tanahashi J, Fujioka T, et al. (2009) Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. Antimicrobial Agents and Chemotherapy 53: 3097-3099. doi: 10.1128/AAC.01552-08 PMID: 19380599
24. Arévalo-Galvis A, Trespalacios-Rangel AA, Otero W, Mercado-Reyes M, Poutou-Piñales RA (2012)Prevalence of cagA, vacA, babA2 and iceA genes in H. pylori strains isolated from Colombian patients with functional dyspepsia. Polish Journal of Microbiology 61: 33-40. PMID: 22708344
25. Podzorski RP, Podzorski DS, Wuerth A, Tolia V (2003) Analysis of the vacA, cagA, cagE, iceA, and babA2 genes in Helicobacter pylori from sixty-one pediatric patients from the Midwestern United States. Diagnostic Microbiology and Infectious Disease 46: 83-88. PMID: 12812722
26. Cittelly DM, Huertas MG, Martínez JD, Oliveros R, Posso H, et al. (2002) Los genotipos de Helicobacter pylori en gastritis no atrófica difieren de los encontrados en úlcera péptica, lesiones premalignas y cáncer gástrico en Colombia. Revista Médica de Chile 130: 143-151. doi: 10.4067/S0034-98872002000200003
27. Morales-Espinosa R, Castillo-Rojas G, Gonzalez-Valencia G, Ponce De León S, Cravioto A, et al. (1999) Colonization of Mexican Patients by Multiple Helicobacter pylori Strains with Different vacA and cagA Genotypes. Journal of Clinical Microbiology 37: 3001-3004. PMID: 10449490
28. García CA, Barra TR, Delgado SchC, Kawaguchi PF, Trabal FN, et al. (2006) Genotipificación de aislados clínicos de Helicobacter pylori en base a genes asociados a virulencia cagA, vacA ybabA2. Primer aislamiento de una cepa babA2 positiva en pacientes chilenos. Revista Médica de Chile 134: 981-988. doi: 10.4067/S0034-98872006000800006
29. Figueiredo C, van Doorn LJ, Nogueira C, Soares JM, Pinho C, et al. (2001) Helicobacter pylori genotypes are associated with clinical outcome in Portuguese patients and show a high prevalence of infections with multiple strains. Scandinavian Journal of Gastroenterology 36: 128-135. PMID: 11252403
30. Blaser MJ (1997) The versatility of Helicobacter pylori in the adaptation to the human stomach. Journal Physiology and Pharmacology 48: 307-314.
31. Camargo MC, García A, Riquelme A, Otero W, Camargo CA, et al. (2014) The Problem of Helicobacter pylori Resistance to antibiotics: a systematic review in Latin America. American Journal of Gastroenterology 109: 485-495. doi: 10.1038/ajg.2014.24 PMID: 24589670
32. Gutiérrez O, Otero W (1998) Resistencia del Helicobacter pylori al metronidazol en Colombia. Revista Colombiana de Gastroenterología 12: 31-36.
33. Álvarez A, Moncayo JI, Santacruz JJ, Corredor LF, Reinosa E, et al. (2009) Resistencia a metronidazol y claritromicina en aislamientos de Helicobacter pylori de pacientes dispépticos en Colombia. Revista Médica de Chile 137: 1309-1314.
34. Trespalacios AA, Otero W, Caminos JE, Mercado MM, Ávila J, et al. (2013) Phenotypic and genotypic analysis of clarithromycin-resistant Helicobacter pylori from Bogotá D.C., Colombia. The Journal of Microbiology 51: 448-452. doi: 10.1007/s12275-013-2465-6 PMID: 23990295
35. Acosta CP, Hurtado FA, Trespalacios A (2014) Determination of single nucleotide mutations in the 23S rRNA gene of Helicobacter pylori related to clarithromycin resistance in a population from Cauca, Colombia. Biomédica 34: 156-162. doi: 10.1590/S0120-41572014000500018 PMID: 24968047
36. Gómez M, Otero W, Gutiérrez Ó (2007) Helicobacter pylori infection treatment. Survey performed by a group of general practitioners and specialist in Colombia. Revista Colombiana de Gastroenterología 22: 7-16.
37. Paoluzi OA, Del Vecchio Blanco G, Visconti E, Coppola M, Fontana C, et al. (2015) Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy. World Journal of Gastroenterology 21: 6698-6705. doi: 10.3748/wjg.v21.i21.6698 PMID: 26074708
38. Caliskan R, Tokman HB, Erzin Y, Saribas S, Yuksel P, et al. (2015) Antimicrobial resistance of Helicobacter pylori strains to fi ve antibiotics, including levofloxacin, in northwestern Turkey. Revista da Sociedade Brasileira de Medicina Tropical 48: 278-284. doi: 10.1590/0037-8682-0027-2015 PMID: 26108005
39. Phan TN, Santona A, Tran VH, Tran TNH, Le VA, et al. (2015) High rate of levofloxacin resistance in a background of clarithromycin-and metronidazole-resistant Helicobacter pylori in VietnamTrung. International Journal of Antimicrobial Agents 45: 244-248. doi: 10.1016/j.ijantimicag.2014.10.019 PMID: 25499186
40. Zhang Y-X, Zhou L-Y, Song Z-Q, Zhang J-Z, He L-H, et al. (2015) Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: A prospective serial study. World Journal of Gastroenterology 21: 2786-2279. doi: 10.3748/wjg.v21.i9.2786 PMID: 25759550
41. Kocazeybek B, Tokman HB (2015) Prevalence of primary antimicrobial resistance of H. pylori in Turkey: a systematic review. Helicobacter IN PRESS. doi: 10.1111/hel.12272
42. Megraud F (2012) The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. Therapeutic Advances in Gastroenterology 5: 103-109. doi: 10.1177/1756283X11432492 PMID: 22423259
43. Rimbara E, Noguchi N, Kawai T, Sasatsu M (2012) Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB. Helicobacter 17: 36-42. doi: 10.1111/j.1523-5378.2011.00912.x
44. Liou JM, Chang CY, Sheng WH, Wang YC, Chen MJ, et al. (2011) Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin and clarithromycin-based therapies. Antimicrobial Agents and Chemotherapy 55: 1123-1129. doi: 10.1128/AAC. 01131-10 PMID: 21189342
45. Cambau E, Allerheiligen V, Coulon C, Corbel C, Lascols C, et al. (2009) Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. Journal of Clinical Microbiology 47: 3600-3607. doi: 10.1128/JCM.00744-09 PMID: 19759218
46. Garcia M, Raymond J, Garnier M, Cremniter J, Burucoa C (2012) Distribution of Spontaneous gyrA mutations in 97 fluoroquinolone-resistant Helicobacter pylori isolates collected in France. Antimicrobial Agents and Chemotherapy 56: 550-551. doi: 10.1128/AAC.05243-11 PMID: 22064536
47. Teh X, Khosravi Y, Lee WC, Leow AH, Loke MF, et al. (2014) Functional and molecular surveillance of Helicobacter pylori antibiotic resistance in Kuala Lumpur. Plos One 9: e101481. doi: 10.1371/journal. pone.0101481 PMID: 25003707
48. Seck A, Burucoa C, Dia D, Mbengue M, Onambele M, et al. (2013) Primary antibiotic resistance and associated mechanisms in Helicobacter pylori isolates from Senegalese patients. Annals of Clinical Microbiology and Antimicrobials 12: 3. doi: 10.1186/1476-0711-12-3 PMID: 23298145
49. Clinical and Laboratory Standards Institute (2010) Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. M100-S20. Vol. 30 No. 31: 160 p.
50. Kim JM, Kim JS, Kim N, Jung HC, Song IS (2005) Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. Journal of Antimicrobial Chemotherapy 56: 965-967. doi: 10.1093/ jac/dki334 PMID: 16159928
51. Wueppenhorst N, Stueger H-P, Kist M, Glocker E (2009) Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany. Journal of Antimicrobial Chemotherapy 63: 648-653. doi: 10.1093/jac/dkp003 PMID: 19190100
52. Tankovic J, Lascols C, Sculo Q, Petit JC, Soussy CJ (2003) Single and double mutations in gyrA but Not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrobial Agents and Chemotheraphy 47: 3942-3944.